A commentary on PSA velocity and doubling time for clinical decisions in prostate cancer. Read more about A commentary on PSA velocity and doubling time for clinical decisions in prostate cancer.
Probability of an abnormal screening prostate-specific antigen result based on age, race, and prostate-specific antigen threshold. Read more about Probability of an abnormal screening prostate-specific antigen result based on age, race, and prostate-specific antigen threshold.
Serial prostate biopsy and risk of lower urinary tract symptoms: results from a large, single-institution active surveillance cohort. Read more about Serial prostate biopsy and risk of lower urinary tract symptoms: results from a large, single-institution active surveillance cohort.
Recent trends in the urology workforce in the United States. Read more about Recent trends in the urology workforce in the United States.
Patient demographics, quality of life, and disease features of men with newly diagnosed prostate cancer: trends in the PSA era. Read more about Patient demographics, quality of life, and disease features of men with newly diagnosed prostate cancer: trends in the PSA era.
Benign prostate glandular tissue at radical prostatectomy surgical margins. Read more about Benign prostate glandular tissue at radical prostatectomy surgical margins.
Long-term follow-up of a phase II trial of chemotherapy plus hormone therapy for biochemical relapse after definitive local therapy for prostate cancer. Read more about Long-term follow-up of a phase II trial of chemotherapy plus hormone therapy for biochemical relapse after definitive local therapy for prostate cancer.
